WA-SPIE
17.12.2020 17:07:15 CET | Business Wire | Press release
SPIE Photonics West , which normally convenes in San Francisco, will be held as an interactive, virtual conference 6-11 March 2021. North America’s largest optics and photonics technology event – with its popular BiOS, LASE, and OPTO conferences – held by SPIE, the international society for optics and photonics , also includes two digital exhibitions and the industry-focused Quantum West. Registration for SPIE Photonics West will open 5 January.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201217005110/en/
In addition to SPIE Photonics West, the following SPIE 2021 conferences will also be held via the organization’s digital-forum platform: SPIE Advanced Lithography ; SPIE Medical Imaging ; SPIE AR/VR/MR ; and SPIE Smart Structures + Nondestructive Evaluation .
“The SPIE Digital Forum platform was developed to help people share results and make connections during the pandemic, and we’ve continued to fine-tune our virtual platform and digital offerings throughout this year,” says SPIE CEO Kent Rochford. “We’ll be implementing the latest improvements during Photonics West and are excited to release them to our attendees, presenters, and exhibitors. These forums, as always, ensure the professional discussion, innovation sharing, and networking opportunities that the SPIE community values and relies on to advance its research, product development, and engineering collaborations.”
"It's been a challenging year for our entire community, and I know that I am not alone in my desire to meet in person to exchange ideas, research, technological advances, and new products," says 2020 SPIE President John Greivenkamp. "We are hopeful of being able to gather in person later in 2021. In the meantime, I invite you to join us online at one or more of these dynamic conferences and look forward to seeing you there."
Each year, SPIE Photonics West showcases the latest in applications, technologies, and discoveries in optics and photonics, with three major conference tracks: BiOS, highlighting new research in biophotonics, biomedical optics, and applications of medical imaging; LASE, with its focus on the laser industry and applications; and OPTO, showcasing optoelectronics, photonic materials, and related devices. In addition, the symposium is introducing a new conference, highlighting photonics research and technologies addressing COVID-19 . Photonics West will also feature a Digital Marketplace with product demos showcasing the latest in optics and photonics technologies and opportunities to connect with the industry’s leading suppliers and companies.
The SPIE Digital Forums will offer a convenient, high-quality, and timely way for researchers, engineers, and government and industry leaders in the photonics community to share emerging research, new results, and technological advances with their peers. The SPIE online format makes presentations and discussion accessible during the Forum in whatever time zone is convenient for the participant and in any order. In addition, the Digital Forums will include networking opportunities, live plenary sessions, and special events. All conference presentations and manuscripts will be accessible after the conference via the SPIE Digital Library . Registration and pricing information is available on each event webpage.
About SPIE
SPIE is the international society for optics and photonics, an educational not-for-profit organization founded in 1955 to advance light-based science, engineering, and technology. The Society serves more than 258,000 constituents from 184 countries, offering conferences and their published proceedings, continuing education, books, journals, and the SPIE Digital Library. In 2020, SPIE provided over $5.8 million in community support including scholarships and awards, outreach and advocacy programs, travel grants, public policy, and educational resources. www.spie.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201217005110/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom